Stopped: Slow Enrollment
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Excluding Deaths Due to Disease Progression
Timeframe: Start of treatment to 28 days post treatment; mean overall duration of talazoparib exposure was 88.7 days.
Number of Participants With Laboratory Abnormalities (Hematology, Clinical Chemistry) at More Than 1 Clinic Visit
Timeframe: Hematology: screening, cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, end of treatment (EOT). Clinical chemistry parameters: screening, cycle 1 day 1, cycle 1 day 8, cycle 1 day 15, cycle 1 day 22, cycle 2 day 1, cycle 2 day 15, EOT.
Number of Participants With Dose-Limiting Toxicities (DLTs)
Timeframe: During Cycle 1 on Days 1 through 28, inclusive
Overall Response Rate (ORR)
Timeframe: Maximum duration of follow-up for ORR was 12.9 months.
Confirmed ORR (cORR)
Timeframe: Maximum duration of follow-up for cORR was 12.9 months.
Clinical Benefit Rate (CBR)
Timeframe: Maximum duration of follow-up for CBR was 12.9 months.
Progression-Free Survival (PFS)
Timeframe: Maximum duration of follow-up for PFS was 12.9 months.